Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 6, 2012

Primary Completion Date

January 9, 2015

Study Completion Date

December 1, 2020

Conditions

Stage III Ovarian Epithelial CancerStage III Ovarian Germ Cell TumorStage IV Ovarian Epithelial CancerStage IV Ovarian Germ Cell Tumor

Interventions

BIOLOGICAL

pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine

Given ID

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT01322802 - Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter